# 📣​Breaking News: We're setting our sights on a Hong Kong IPO | Axiom Biosciences

- Canonical URL: https://wefunder.com/feed/355527
- Entity ID: wefunder:feed_item:355527
- Published at: 2026-07-22 22:06:58 UTC
- Updated at: 2026-07-22 22:06:59 UTC

## Author
Remo Moomiaie

## Subject
Axiom Biosciences

## Content
I have some big news: we're targeting a Hong Kong IPO in 2027, with a NASDAQ listing to follow in 2029 🚀We’re the first American company to list on the Hong Kong stock exchange.This is a contrarian move for a U.S.-based biotech, and that's exactly why we're making it. Here are three reasons we chose this path:🔬 Hong Kong has built one of the most sophisticated biotech investor networks in the world. These are investors who understand the timelines, the risks, and the capital needs of next-generation science. Since 2018, 86 companies have listed there, raising over $17.8 billion, and recent biopharma listings in Hong Kong have outperformed those on the Nasdaq.🤝 Asia brings us closer to clinical and commercial partners who can help us move faster and more efficiently. Our stem cell therapy for newborns with severe brain injuries has no approved alternative anywhere in the world. Speed matters, and proximity to the right partners gets us to patients sooner.🌍 This is the first step in building a truly global biotech company. The science was born in the U.S., and we intend to bring it to patients everywhere. A Hong Kong listing followed by NASDAQ positions Axiom on two of the world's most important capital markets.This milestone comes after a strong run of momentum: positive Phase 1 results, growing attention to our science, and our rebrand from Cytonus to Axiom Biosciences, a name that better reflects the company we're building.None of this happens without you. Every person who invested early, shared our story, or cheered us on is part of what made this possible.👉 Increase your investment before the round sells out: https://wefunder.com/axiombiosciences/investHere's to the road ahead; and to building it together.Remo Moomiaie-Qajar, MDFounder & CEO, Axiom Biosciences